Key Points
The Cooper Companies, Inc. (COO) rallied sharply in today’s session, delivering a clean upside move that stood out on a generally steady tape. After a previous close of $77.03, shares finished at $84.25, gaining 9.37% and advancing $7.22 on the day. The price action reflected sustained buying interest from the open through the close, with bids stepping higher throughout the session and supporting a constructive intraday tone. Trading volume of roughly 1,418,884 shares came in below the 90-day average of about 2,709,798, signaling a decisive move higher without the froth that often accompanies heavy turnover.
Momentum remained favorable into the afternoon, with the stock extending gains and holding them, a sign that investors were comfortable with the new price level. Even after the jump, COO remains 19% below its 52-week high of $104.47 set on 12/05/2024, leaving room for recapture should the improving narrative continue. That distance can serve as an upside reference point for investors tracking the recovery path, especially as the company’s fundamentals and outlook firm up.
Today’s advance also reinforces an improving near-term trend and suggests growing confidence in management’s execution. The measured nature of the bid—strong price appreciation on below-average volume—implies investors were responding to specific company drivers rather than broad market swings. With the close comfortably above the prior day’s level, COO’s price structure has improved, reflecting favorable momentum and a positive shift in sentiment that can carry into the next trading sessions if catalysts continue to validate the story.
Why The Cooper Companies, Inc. Price is Moving Higher
COO’s strong move to $84.25 was driven by tangible company-specific catalysts and supportive metrics. The company reported Q4 fiscal 2025 results that outpaced expectations, with adjusted EPS of $1.15 topping the $1.11 consensus and rising 11% year over year. Revenue came in at $1.065 billion, edging past the $1.06 billion estimate and growing 5% on a reported basis (3% organically). While GAAP EPS registered at $0.43, down 27% year over year, management highlighted operational improvements and AI-driven integration efforts expected to produce roughly $50 million in annual savings. Combined with a 10% increase in three-year free cash flow targets to $2.2 billion, these actions point to improved operating margins and cash generation ahead.
Momentum was reinforced by positive sell-side reactions. Needham raised its price target to $100 and reiterated a Buy rating, citing the quarter’s outperformance, a rising free cash flow outlook, and a formal strategic review that could lead to a separation of CooperVision (CVI) and Custom Surgical Innovations (CSI). Stifel increased its price target to $95 and expects CVI growth of about 5% in fiscal 2026, underscoring confidence in the core lens franchise’s trajectory.
Despite a 70-basis-point decline in adjusted gross margin to 66% due to product mix and tariffs, investors appeared to look through temporary headwinds in favor of guidance that topped expectations and a reorganization designed to support sustained profitability. With a market cap of $15.31 billion, EPS (TTM) of $2.03, and shares still below the 52-week high of $104.47, today’s +9.4% surge on 1,418,884 shares (versus a 90-day average of 2,709,798) reflects bullish momentum, growing investor enthusiasm, and confidence in COO’s forward path.
What is the The Cooper Companies, Inc. Rating - Should I Buy?
Weiss Ratings assigns COO a C rating. Current recommendation is Hold.
The rating is built on five indices: the Excellent Growth Index (measures revenue and earnings expansion) aligns with recent topline and earnings progress, supported by 5.73% revenue growth. The Good Efficiency Index (measures operational effectiveness and profit margins) is consistent with a 10.07% profit margin and disciplined cost control. The Excellent Solvency Index (measures financial health and debt management) reflects a strong balance sheet and prudent leverage, supporting resilience through cycles.
Balancing these strengths, the Weak Total Return Index (measures stock price appreciation plus dividends) points to lagging risk-adjusted performance versus alternatives, in part as the stock consolidates prior gains. The Weak Volatility Index (measures price stability and risk) indicates higher price swings, a factor that can dampen risk-adjusted outcomes. Valuation also plays a role: a 37.89 P/E Ratio and 5.01% ROE suggest investors are paying for growth that must be consistently delivered to sustain multiple support.
Compared with peers, sector leaders LLY (B) and JNJ (B) carry higher overall ratings and stronger risk-adjusted track records, while ABBV sits at C. COO’s C places it in the middle of the pack, with a differentiated focus in Health Care Equipment and Services versus large-cap biopharma peers.
Overall, the mix of Excellent Growth and Solvency with Weak Total Return and Volatility produces a balanced, risk-aware profile. That’s why COO earns a C (Hold): solid fundamentals and financial strength, tempered by choppier trading and average risk-adjusted returns that the company is working to improve.
About The Cooper Companies, Inc.
The Cooper Companies, Inc. is a global medical device company operating in the Health Care sector within the Health Care Equipment and Services industry. The company focuses on vision care and women’s health solutions, providing products that address daily needs for patients and clinicians while generating recurring demand across its installed base and consumable portfolios.
Through CooperVision, the company designs and manufactures a comprehensive range of soft contact lenses. Its offerings span daily disposables, two-week and monthly modalities, and specialty designs, including toric lenses for astigmatism and multifocal lenses for presbyopia. CooperVision’s portfolio serves a wide array of prescriptions and ocular conditions, with well-known franchises positioned for comfort, oxygen permeability, and consistent optical performance. The business supports eye care professionals globally through training, practice tools, and reliable logistics that facilitate patient adoption and retention.
CooperSurgical focuses on women’s health, fertility, and family-building solutions. The business provides IVF consumables and laboratory equipment used by fertility clinics, along with genetic testing services that support reproductive planning. It also offers a range of devices and medical products utilized in obstetrics and gynecology practices, emphasizing clinician workflow, safety, and patient outcomes. The portfolio’s mix of capital equipment and high-margin consumables creates durable relationships with clinics and providers.
Cooper’s competitive advantages include deep clinical relationships, a broad product catalog tailored to specialized needs, robust quality and regulatory capabilities, and a global distribution footprint. Its combination of recurring consumables, specialty products, and customer support helps drive predictable demand and positions the company to benefit from long-term trends in vision correction and fertility care.
Investor Outlook
Today’s move reflects strengthening fundamentals, rising free cash flow visibility, and supportive analyst commentary. A C (Hold) rating indicates a balanced risk/reward profile while the company executes on cost savings and growth initiatives.
For investors tracking COO, continued delivery against guidance and strategic milestones could sustain momentum. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.